☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Christopher J. Calhoun
Merck Reports Results of Arpraziquante in P-III Clinical Trial for the Treatment of Schistosomiasis
November 17, 2021
PharmaShots Interview: Paracrine's Christopher J. Calhoun Shares Insight on the First Autologous, Device-Based Cell Therapy Platfo...
November 16, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.